Articles
Issue Editorial Board
Aim & Scope
Journal of Research in Pharmacy is the official scientific journal of Marmara University Faculty of Pharmacy. The journal is the continuation of the former "Journal of Pharmacy of University of Marmara" which was published between 1985 and 1997. Since 2010, the journal has been published online bimonthly (January-March-May-July-September-November). It is an open access, peer-reviewed journal devoted to the publication of papers in pharmacy and pharmaceutical sciences. The journal only accepts articles written in English for evaluation. The journal aims at providing a medium for the dissemination of interdisciplinary papers of interest for many different specialists.
Journal of Research in Pharmacy publishes original research papers, review articles and scientific commentaries on all aspects of pharmaceutical sciences depending on their conceptual novelty and scientific quality. The journal welcomes articles in this multidisciplinary field, with a focus on topics relevant for drug action, drug discovery and development, conventional and emerging fields related to pharmaceutical sciences. Articles, which cannot be associated with pharmaceutical issues in any way, might be returned to authors without processing. Scientific commentaries and review articles are generally evaluated by invitation or assent of the Editors. Proceedings of scientific meetings may also be published as special issues or supplements to the Journal, upon decision by the editors.
Manuscripts submitted to Journal of Research in Pharmacy are only accepted on the comprehension that (I) they are subject to editorial review (at least by two independent referees); (II) they have not been, and will not be fully or partially published elsewhere; (III) the recommendations of the most recent version of the Declaration of Helsinki, for humans, and the European Community guidelines as accepted principles for the use of experimental animals have been adhered to.
The editorial and publication processes of the journal are conducted in accordance with the guidelines of the International Committee of Medical Journal Editors (ICMJE), World Association of Medical Editors (WAME), Council of Science Editors (CSE), Committee on Publication Ethics (COPE), European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal is in conformity with the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).
Processing and publication are free of charge with the journal. Fees are not requested from the authors at any point during the evaluation and publication period. All published content is available online, free of charge at www.jrespharm.com. Corresponding authors should submit their manuscripts through the online submission system, which is accessible at www.jrespharm.com. The journal guidelines, technical information, and the required forms are available on the journal’s website.
Statements or views stated in the manuscripts published in the journal reflect the views of the author(s) and does not represent opinions of the Marmara University Faculty of Pharmacy, editors, editorial board, and/or publisher. The editors, editorial board, and publisher disapprove any responsibility or liability for such materials.
Marmara University Faculty of Pharmacy retains the international copyright of all the content published in the journal.
Writing Rules
MANUSCRIPT PREPARATION
Authors must use our manuscript template which is accessible at our website and article submission system (https://www.jrespharm.com/static.php?id=7). This will facilitate manuscript preparation and may prevent delays due to returning of your article at technical check stage. Manuscripts should contain the following elements in the following order:
Title
Author names, affiliations
Abstract
Keywords
Introduction
Results
Discussion
Conclusion
Materials and Methods
Acknowledgements
Authorship statement
Conflict of interest statement
References
Tables and figures should be placed where they are related, not in a separate section at the end of the article.
5.1. TITLE
Title should be concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae, where possible. Titles are of great importance for current awareness and for information retrieval. The wording of titles should be chosen carefully to provide information on the contents and to function as "points of entry" for information retrieval. Symbols, formulas, or arbitrary abbreviations should not be included in the title, except chemical symbols to indicate the structure of isotopically labeled compounds. Full title must be in sentence case. The title of the manuscript must be written in lower case except for the first word and proper nouns.
5.2. AUTHOR NAMES AND AFFILIATIONS
Author names must be given in full, with surnames (family names) all in capitals.
Where names may be ambiguous (e.g., a double name, or possible confusion about first/last names), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript number immediately after the author's name and in front of the appropriate address. Author addresses must be given in English in the following order: Department, Faculty, University, City, Country, with numbers in superscript after each author name to indicate his/her address. Provide the full postal address of each affiliation, including the country name for each author.
5.2.1. Present/permanent address
If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
5.2.2. Corresponding Author
You should designate one author to act as corresponding author. Note that this is the person who will receive correspondence from Journal of Research in Pharmacy editorial office and needs to be the person who will appear as corresponding author on the paper if accepted.
The manuscript has to be submitted online by the person who is in charge of correspondence at all stages of the editorial process, production, and post-publication. Ensure that phone/fax numbers with country and area codes) are provided, in addition to the e-mail address (preferably an institutional e-mail address) and the complete postal address. Contact details of the other authors must be kept up to date by the corresponding author.
5.3. ABSTRACT
A concise and factual abstract, which is unstructured, is required. The abstract is limited to 250 words or less for research and review articles and, 200 words or less for commentaries. The abstract should state briefly the purpose of the research, experimental approach, the principal results and major conclusions. An abstract is often presented separately from the article, so the text should be comprehensible when read alone. For this reason, references should be avoided.
The use of numbers in the abstract identifying compounds, formulas, tables or references and non-standard or uncommon abbreviations should be avoided. However, if essential, they must be defined at their first mention in the abstract.
5.4. KEY WORDS
Each submission must be accompanied by a minimum of four to a eight keywords that reflect the scientific content of your manuscript for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible.
5.5. INTRODUCTION
In this section, the authors should state the objectives of the work, define the scope of your paper, summarize relevant work to the study being reported and provide an adequate background. A detailed literature survey or a summary of the results should be avoided. It should not be a review of the subject area, but should finish with a clear statement of the question being addressed. The introduction must be designed to inform the reader of the rationale and significance of the study.
5.6. RESULTS AND DISCUSSION 5.6.1.
Results
Results should be clear and concise. Text, tables and figures must show minimal overlap, and must be internally consistent. Tables and figures should be designed to maximize the presentation and comprehension of the experimental data. Attention should be paid to the matter of significant figures (usually, no more than three). The same data should not be presented in more than one figure or in both a figure and a table. As a rule, interpretation of the results should be reserved for the discussion section of a Research Article, but under some circumstances it may be desirable to combine results and discussion in a single section.
5.6.2. Discussion
The Results and Discussion sections may be combined. Avoid extensive citations and discussion of published literature. The purpose of the discussion is to interpret significance of the results and to relate them to existing knowledge in the field in as clear and brief a fashion as possible. Information given elsewhere in the manuscript should not be repeated in the discussion. Extensive reviews of the literature should be avoided.
5.7. CONCLUSIONS
The main conclusions of the study should be presented in a short Conclusions section, which stands alone. You should explain whether your findings supported your hypothesis. Avoid using references in conclusion section.
5.8. MATERIALS AND METHODS
Methods already published should be indicated by a reference: only relevant modifications should be described.
The experimental procedures should be described in sufficient detail to enable others to repeat the experiments. Names of products and manufacturers (with locations) should be supplied for all mentioned equipment, instruments, chemicals, etc. Brand names may be used only once in the manuscript. For subsequent designation, use "formulation A", product B", etc. Novel experimental procedures should be described in detail, but published procedures should merely be referred to by literature citation of both the original and any published modifications. The purity of key compounds and descriptions(s) of the method(s) used to determine purity should be included in this section. For buffers, use terminology such as "20 mM potassium phosphate buffer (pH 7.7) containing...". Also, state w/v or v/v when appropriate. Identification of and precautions for handling hazardous chemicals and dangerous procedures should be placed at the beginning of the section. An example would be " Caution: The following chemicals are hazardous and should be handled carefully; (list of chemicals and handling procedures or references) ". Manuscripts containing data generated from animal and/or human studies must specify the committee and the institution that approved the experimental protocols used to generate these data.
5.8.1. Characterization of the synthesized compounds
Sufficient experimental information should be given by the authors. A melting point range should be reported for every crystalline solid product, together with the solvent from which it was recrystallized, and a description of the material e.g. “yellow needles, mp 123-124 ºC (from ethanol)”. For all synthesized compounds (new or previously reported), evidence to confirm both identity and purity have to be provided. Evidence for the identity of new compounds should include both elemental analysis and 1H NMR data. 13C NMR data of at least some key structures should be present. Evidence for the identity of new compounds should include, 1H NMR data and either HRMS (resolution 0.001 m/z unit or better) or elemental analysis data to support the molecular formula assignment. In case HRMS is preferred to elementel analysis, HPLC chromatograms should be provided as supplementary material.
To facilitate reviewing process, the authors are encouraged to submit a list of compounds as a separate file. In this list, previously reported and new compounds should be classified. Chemical structures and SMILES codes of all compounds should be supplied, together with the names of the characterization techniques used for each compound. This form should be uploaded as Supplementary material (for reviewing purposes only).
5.9. ACKNOWLEDGEMENTS
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. This section should acknowledge financial support, help from a lab technician or statistician, advice from colleagues, gifts, etc. Permission must be received from persons whose contribution to the work is acknowledged in the manuscript.
5.10. AUTHORSHIP STATEMENT
Author contributions should be written right before conflict of interest statement, in accordance with JRP – Copyright Transfer Agreement signed by the authors. Please use initials instead of full names. It should appear as follows :
Author contributions: Concept – İ.K., E.T.; Design – İ.K., E.T.; Supervision – E.T.; Resource – İ.K.; Materials – N.K., A.D.; Data Collection &/or Processing - N.K., A.D.; Analysis &/or Interpretation - N.K., A.D.; Literature Search – İ.K., E.T., N.K., A.D.; Writing – E.T., İ.K.; Critical Reviews – İ.K., E.T., N.K., A.D.
5.11. CONFLICT OF INTEREST STATEMENT
Journal of Research in Pharmacy requires and encourages the authors and the reviewers involved in the evaluation process of submitted manuscripts to disclose any existing or potential conflicts of interests, including financial, consultant, and institutional, that might lead to potential bias or a conflict of interest. Any financial grants or other support received for a submitted study from individuals or institutions should be disclosed to the Editorial Board.
If there is no conflict of interest to be declared by any of the authors, write “The authors declared no conflict of interest” in the manuscript.
5.12. REFERENCES 5.12.1. Citation in text
While citing publications, preference should be given to the latest, most up-to-date publications. References should conform to Vancouver style and be numbered consecutively in the order in which they are cited in the text. Cite in the text by the appropriate Arabic numeral enclosed in square brackets, e.g., [1], [2-5], etc. Authors are responsible for the accuracy of references. All references cited in the manuscript must appear in the list of references at the end and all references listed in the reference list must be cited in the manuscript. Do not include personal communications, unpublished data, or other unpublished materials as references. In the case of cited publications in languages other than English, the published English title should be provided if one exists, with an annotation such as “(article in Turkish with an abstract in English)”. If the publication was not published with an English title, provide the original title only; do not provide a self-translation.
5.12.2. Web references
Although web references is not recommended by Journal of Research in Pharmacy, some circumstances might be considered as exceptional cases. These are: Websites of governmental organizations (ie. ministries of health, FDA), international organizations (ie. WHO, EMA, ICH, EFMC), online calculation tools (ie. Molinspiration, VCCLAB).
5.12.3. Formatting
Journal titles should be abbreviated in accordance with the journal abbreviations in Thomson Reuters Web of Science, Index Medicus/ MEDLINE/PubMed. For all journal articles (including articles in press) in the reference list, the DOI numbers should be provided (ie. http://dx.doi.org/10.1016/j.ejmech.2016.05.017). The reference styles for different types of publications are presented in the following examples.
5.12.4. Examples
Reference to a journal publication:
[1] Tatar E, Küçükgüzel İ, Daelemans D, Talele TT, Kaushik-Basu N, De Clercq E, Pannecouque C. Some hydrazones of 2-aroylamino-3-methylbutanohydrazide: synthesis, molecular modeling studies, and identification as stereoselective inhibitors of HIV-1. Arch Pharm (Weinheim). 2013; 346(2): 140-153. http://dx.doi.org/10.1002/ardp.201200311.
[2] Tatar E, Karakuş S, Küçükgüzel ŞG, Öktem Okullu S, Ünübol N, Kocagöz T, De Clercq E, Andrei G, Snoeck R, Pannecouque C, Kalaycı S, Şahin F, Sriram D, Yogeeswari P, Küçükgüzel İ. Design, synthesis, and molecular docking studies of a conjugated thiadiazole-thiourea scaffold as antituberculosis agents. Biol Pharm Bull. 2016; 39(4): 502-515. http://dx.doi.org/10.1248/bpb.b15-00698.
[3] Kulabaş N, Bingöl Özakpınar Ö, Özsavcı D, Leyssen P, Neyts J, Küçükgüzel İ. Synthesis, characterization and biological evaluation of thioureas, acylthioureas and 4-thiazolidinones as anticancer and antiviral agents. J Res Pharm. 2017; 21(2): 371-384. http://dx.doi.org/10.12991/marupj.300913.
Reference to a book:
2. Silverman RB, The Organic Chemistry of Drug Design and Drug Action, third ed., Elsever, Burlington, MA, USA 2014.
Reference to a chapter in an edited book:
3. Şener G, Sakarcan A, Yeğen B. Melatonin as a radioprotective agent. In: Montilla P, Túnez I. (Eds). Melatonin: Present and Future. Nova Science Publishers, Inc., New York, 2008, pp.127-142.
Theses
4. Tatar E. PhD Thesis. Synthesis and characterization of novel 1,3-thiazolidine-4-ones derived from 2-(aroylamino)-3-methyl butyric acid hydrazide. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Haydarpaşa, İstanbul, Turkey, 2009.
Reference to a website:
5. VCCLAB, Virtual Computational Chemistry Laboratory. http://www.vcclab.org (accessed March 18, 2017).
6. PASS (Prediction of Activity Spectra for Substances) program. http://www.way2drug.com/passonline(accessed July 18, 2015).
7. WHO Global tuberculosis report 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf?ua=1, (accessed July 18, 2015).
5.13. TABLES
Please submit tables as editable text and not as images. Tables should be placed next to the relevant text in the article. They should not be given on separate page(s) after the references. Number tables consecutively in accordance with their appearance in the text and place any table footnotes below the table body. Table headings should be given above the table and written in sentence case. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.
5.14. FIGURES
All artworks, figures, images, illustrations, graphics, photos, pictures, plots and schemes should be labeled as Figures. Figures must be submitted both in the manuscript and as separate files. Inclusion of the figures in the manuscript should be done using add pictures command under insert tab – do NOT use copy and paste function. All tables and figures must have a caption and/or legend and be numbered (e.g., Table 1, Figure 2), unless there is only one table or figure, in which case it should be labelled “Table” or “Figure” with no numbering. Captions must be written in sentence case (e.g., Physical and spectral data of the synthesized compounds.). The font used in the figures should be Times New Roman. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
All tables and figures must be numbered consecutively as they are referred to in the text. Please refer to tables and figures with capitalisation and unabbreviated (e.g., “As shown in Figure 2…”, and not “Fig. 2” or “figure 2”). The tables and figures themselves should be given in the running text. They should not be given at the end of the text only, after the references.
To ensure the highest print quality, your figures should be submitted in either TIFF or JPEG format at the highest possible resolution (300 dpi or higher). The authors should obtain written permission from the respective publishers to reproduce any images from other sources, even if they are quoted from their previous papers.
5.14.1. Image manipulation
Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.
Please do not:
Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
Supply files that are too low in resolution;
Submit graphics that are disproportionately large for the content.
Table 1. Limitations of JRP for each manuscript type.
Word limit
(main text only)
Word limit (Abstract)
Reference limit
Table limit
Figure limit
Keyword limit
Research Article
max. 5500
300
Max. 80
Max. 8
Max. 8
4-8
Review Article
No limits
250
Min. 50
No limits
No limits
4-8
Commentary
max. 2500
200
Max. 30
Max. 4
Max. 4
Max. 6
Letter to Editor
max. 1000
No abstract
Max. 10
No tables
No figures
No keywords
Ethical Principles and Publication Policy
Manuscripts submitted to Journal of Research in Pharmacy are only accepted on the comprehension that (I) they are subject to editorial review (at least by two independent referees); (II) they have not been, and will not be fully or partially published elsewhere; (III) the recommendations of the most recent version of the Declaration of Helsinki, for humans, and the European Community guidelines as accepted principles for the use of experimental animals have been adhered to. The Journal of Research in Pharmacyl will, therefore, only consider manuscripts that describe experiments which have been carried out under approval of an institutional or local ethics committee.
Journal of Research in Pharmacy serves to further academic discussions of topics, irrespective of their nature – whether religious, gender-based, environmental, ethical, political or other potentially or topically contentious subjects and adopts a neutral position on issues. Publication of an article in our academic peer-reviewed journal involves many parties, the author, the journal editor, the peer-reviewer; each have responsibilities to meet expected ethical standards at all stages in their involvement from submission to publication of an article.
Journal of Research in Pharmacy is committed to meeting and upholding standards of International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE), and National Information Standards Organization (NISO), Budapest Open Access Initiative (BOAI). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice)
Price Policy
Marmara University on behalf of which it publishes shall ensure that good practice is maintained to the standards outlined below. Articles are freely available to both subscribers and the wider public with permitted reuse. No open access publication fee, submission charge, and processing charge payable by authors or on their behalf, e.g. by their research funder or institution.